Using next generation sequencing(NGS) technology, we identify aberrant proteins arising from cancer-specific genetic mutations (neoantigens) while excluding those expressed by normal cells, thereby ensuring precise therapeutic targeting.

Neoantigens need to bind to the major histocompatibility complex (MHC, also known as HLA in humans) in order to be recognized by immune cells such as T cells. We use bioinformatics tools to predict epitopes of neoantigens that can efficiently bind to MHC and identify candidate peptides with strong immunogenicity.

Based on the MHC background and and tumor mutation profiles, we select the most suitable candidate peptide combination based on their tumor molecular profiles, truly achieving personalized therapy—"one patient, one therapy".

By analyzing the spatial structure of peptides through molecular modeling, predicting their stability in binding to T cell receptors (TCRs), and further screening peptide sequences that can efficiently activate immune responses, we identify prime candidates for peptide vaccines.

The designed peptide sequences are chemically synthesized and rigorously purified to remove impurities, ensuring product purity and safety, thereby enabling the efficient production of high-purity peptides that meet GMP standards.

The purified peptides are mixed with adjuvant to formulate stable, easy-to-store and easy-to-use vaccines for clinical applications.Formulations are combined in a defined ratio to develop a stable, easy-to-store and easy-to-transport vaccine preparation.

Actively facilitate regulatory approval of vaccine products, support clinical trials, and accelerate the highly efficient transition from R&D to clinic.